Repligen Corp (RGEN)
Health Care ยท Biological Products, (No Diagnostic Substances)
Repligen Corp (RGEN) is listed on Nasdaq, where its shares have traded since April 29, 1986. SentiSense covers Repligen Corp in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Olivier Loeillot is its chief executive officer. The company reports 2,000 employees, and its corporate website is www.repligen.com.
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 468 institutions reported holding RGEN, with 66.0 million shares worth $9.0 billion in aggregate. The largest reported holders were BlackRock, Vanguard and FMR. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on RGEN
- RGEN sentiment: whether news and social coverage of Repligen Corp leans bullish or bearish, and the stories driving it.
- RGEN ownership: all 468 reporting institutions, plus insider and congressional trades.
- RGEN financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Repligen Corp: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Repligen Corp do?
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies.
What sector is RGEN in?
SentiSense classifies Repligen Corp in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does RGEN stock trade?
Repligen Corp (RGEN) is listed on Nasdaq, where its shares have traded since April 29, 1986.
Who is the CEO of Repligen Corp?
Olivier Loeillot is the chief executive officer of Repligen Corp.